BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 30787107)

  • 1. Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.
    Willem C; Makanga DR; Guillaume T; Maniangou B; Legrand N; Gagne K; Peterlin P; Garnier A; Béné MC; Cesbron A; Le Bourgeois A; Chevallier P; Retière C
    J Immunol; 2019 Apr; 202(7):2141-2152. PubMed ID: 30787107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
    J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
    Shimoni A; Labopin M; Lorentino F; Van Lint MT; Koc Y; Gülbas Z; Tischer J; Bruno B; Blaise D; Pioltelli P; Afanasyev B; Ciceri F; Mohty M; Nagler A
    Leukemia; 2019 Jan; 33(1):230-239. PubMed ID: 29907809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
    Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor Selection Based on Killer Cell Immunoglobulin-Like Receptor (KIR) Genotype May Improve Outcome After T-Cell-Replete Haploidentical Transplantation.
    Torío A; Pascual MJ; Vidales I; Ortiz M; Caballero A; Heiniger AI
    Transplant Proc; 2018 Mar; 50(2):679-682. PubMed ID: 29579887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
    Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the biology of KIR2DL3
    David G; Willem C; Legrand N; Djaoud Z; Mérieau P; Walencik A; Guillaume T; Gagne K; Chevallier P; Retière C
    Sci Rep; 2021 Aug; 11(1):15782. PubMed ID: 34349169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
    Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation.
    Björklund AT; Schaffer M; Fauriat C; Ringdén O; Remberger M; Hammarstedt C; Barrett AJ; Ljungman P; Ljunggren HG; Malmberg KJ
    Blood; 2010 Apr; 115(13):2686-94. PubMed ID: 20097883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor Killer Immunoglobulin-Like Receptor Haplotype B/x Induces Severe Acute Graft-versus-Host Disease in the Presence of Human Leukocyte Antigen Mismatch in T Cell-Replete Hematopoietic Cell Transplantation.
    Hosokai R; Masuko M; Shibasaki Y; Saitoh A; Furukawa T; Imai C
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):606-611. PubMed ID: 28042021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.
    Shilling HG; McQueen KL; Cheng NW; Shizuru JA; Negrin RS; Parham P
    Blood; 2003 May; 101(9):3730-40. PubMed ID: 12511415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Natural Killer Cell-Associated Factors on Acute Leukemia Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation with αβ T Cell Depletion in a Pediatric Cohort.
    Glushkova S; Shelikhova L; Voronin K; Pershin D; Vedmedskaya V; Muzalevskii Y; Kazachenok A; Kurnikova E; Radygina S; Ilushina M; Khismatullina R; Maschan A; Maschan M
    Transplant Cell Ther; 2024 Apr; 30(4):435.e1-435.e12. PubMed ID: 38278183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide.
    Maeda Y
    J Clin Exp Hematop; 2021 Mar; 61(1):1-9. PubMed ID: 33551435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables.
    Solomon SR; Aubrey MT; Zhang X; Piluso A; Freed BM; Brown S; Jackson KC; Morris LE; Holland HK; Solh MM; Bashey A
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):789-798. PubMed ID: 29355721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.
    Gao F; Ye Y; Gao Y; Huang H; Zhao Y
    Front Immunol; 2020; 11():2022. PubMed ID: 32983145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.